Results 41 to 50 of about 2,811,792 (409)
Biological Pathways and Potential Targets for Prevention and Therapy of Chronic Allograft Nephropathy [PDF]
, 2014 Renal transplantation (RT) is the best option for patients with end-stage renal disease, but the half-life is limited to a decade due to progressive deterioration of renal function and transplant failure from chronic allograft nephropathy (CAN), which is
Haylor, John, Shrestha, Badri Man
core +3 more sources
European Journal of Heart Failure, 2020 The SARS‐CoV‐2 virus binds to the angiotensin‐converting enzyme 2 (ACE2) receptor for cell entry. It has been suggested that angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB), which are commonly used in patients ...
D. Bean +13 more
semanticscholar +1 more source
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2019 Background The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of reducing cardiovascular mortality in the PARADIGM‐HF (Prospective ...
Yiwen Wang +5 more
semanticscholar +1 more source
Exploring metabolic dysfunction in chronic kidney disease [PDF]
, 2012 Impaired kidney function and chronic kidney disease (CKD) leading to kidney failure and end-stage renal disease (ESRD) is a serious medical condition associated with increased morbidity, mortality, and in particular cardiovascular disease (CVD) risk ...
Slee, Adrian D.
core +2 more sources
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study
Circulation, 2019 Background: The morbidity and mortality of patients with functional mitral regurgitation (MR) remain high, but no pharmacological therapy has been proven effective. The hypothesis of this study was that sacubitril/valsartan would be superior to valsartan
D. Kang +9 more
semanticscholar +1 more source
HYPERTENSION, 2020 Potential but unconfirmed risk factors for coronavirus disease 2019 (COVID-19) in adults and children may include hypertension, cardiovascular disease, and chronic kidney disease, as well as the medications commonly prescribed for these conditions, ACE ...
A. South, T. Brady, J. Flynn
semanticscholar +1 more source
Enhancement of Adipocyte Browning by Angiotensin II Type 1 Receptor Blockade. [PDF]
PLoS ONE, 2016 Browning of white adipose tissue (WAT) has been highlighted as a new possible therapeutic target for obesity, diabetes and lipid metabolic disorders, because WAT browning could increase energy expenditure and reduce adiposity.
Kana Tsukuda +12 more
doaj +1 more source
Angiotensin Ii Receptor Blockers [PDF]
Baylor University Medical Center Proceedings, 2003 The ARBs have very similar clinical profiles. They do, however, have different pharmacokinetic profiles, which may lead to some differences in efficacy. The newer agents irbesartan, candesartan, telmisartan, and olmesartan have longer half-lives and durations of action than the older agents losartan and valsartan (5).
Amy, Barreras, Cheryle, Gurk-Turner
openaire +2 more sources
Journal of Virology, 2020 The recent emergence of Wuhan coronavirus (2019-nCoV) puts the world on alert. 2019-nCoV is reminiscent of the SARS-CoV outbreak in 2002 to 2003. Our decade-long structural studies on the receptor recognition by SARS-CoV have identified key interactions ...
Yushun Wan +4 more
semanticscholar +1 more source
Evaluation of prescription pattern of anti - Hypertensive drugs in Urban population of Hyderabad
MRIMS Journal of Health Sciences, 2014 Knowledge of existing prescription patterns in the treatment of hypertension can provide useful information for improving clinical practice in this field.
M Jamuna Rani, G Jyothsna, Rohit Singh
doaj +1 more source